Loading...

Ben Braun, MD, PhD

Address550 16th. Street
San Francisco CA 94158
Phone415-514-4176
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California Los AngelesM.D.1998School of Medicine

    Collapse Research 
    Collapse Research Activities and Funding
    Mechanisms linking RAS signals to disordered hematopoiesis and myeloid neoplasia
    NIH R01CA173085Jul 2, 2013 - May 31, 2018
    Role: Principal Investigator
    In Vivo Analysis of Oncogenic Kras in Leukemogenesis
    NIH K08CA103868Jul 1, 2005 - Aug 31, 2010
    Role: Principal Investigator
    Bio-Organic Biomedical Mass Spectrometry Resource
    NIH P41RR001614Mar 1, 1982 - May 31, 2015
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K. A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res. 2017 Oct 09. PMID: 28993414.
      View in: PubMed
    2. Akutagawa J, Huang TQ, Epstein I, Chang T, Quirindongo-Crespo M, Cottonham CL, Dail M, Slusher BS, Friedman LS, Sampath D, Braun BS. Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia. 2016 Jun; 30(6):1335-43. PMID: 26965285.
      View in: PubMed
    3. Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2016 Jan; 126(1):404. PMID: 26727232; PMCID: PMC4701564.
    4. Braun BS. Traxtile: Interactive editing of cell tracks in time-lapse images. Biotechniques. 2015 Aug; 59(2):82-6. PMID: 26260086; PMCID: PMC4560953.
    5. Stieglitz E, Troup CB, Gelston LC, Haliburton J, Chow ED, Yu KB, Akutagawa J, Taylor-Weiner AN, Liu YL, Wang YD, Beckman K, Emanuel PD, Braun BS, Abate A, Gerbing RB, Alonzo TA, Loh ML. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood. 2015 Jan 15; 125(3):516-24. PMID: 25395418; PMCID: PMC4296011.
    6. Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K. PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Sci Signal. 2013 Dec 03; 6(304):ra105. PMID: 24300897; PMCID: PMC4117477.
    7. Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013 Jan; 123(1):335-9. PMID: 23221337; PMCID: PMC3533281.
    8. Braun BS. KIT's ship comes in. Blood. 2012 Sep 27; 120(13):2541-2. PMID: 23019203.
      View in: PubMed
    9. Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012 Oct 25; 120(17):3397-406. PMID: 22898602; PMCID: PMC3482854.
    10. Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med. 2011 Mar 30; 3(76):76ra27. PMID: 21451123; PMCID: PMC3265440.
    11. Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M, Sharma T, Gavin J, Kutok JL, Iscove NN, Shannon KM, Dick JE, Neel BG, Braun BS. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood. 2011 Apr 21; 117(16):4253-61. PMID: 21398220; PMCID: PMC3087477.
    12. Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood. 2011 Feb 10; 117(6):2022-32. PMID: 21163920; PMCID: PMC3056645.
    13. Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Starý J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010 Sep; 42(9):794-800. PMID: 20694012; PMCID: PMC4297285.
    14. Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, Kang HC, Kogan SC, Shokat K, Wolff L, Braun BS, Shannon K. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5106-11. PMID: 20194733; PMCID: PMC2841878.
    15. Braun BS, Shannon K. The SPS affair: a complex tale of illicit proliferation. Cancer Cell. 2009 Aug 04; 16(2):87-8. PMID: 19647218.
      View in: PubMed
    16. Santaguida M, Schepers K, King B, Sabnis AJ, Forsberg EC, Attema JL, Braun BS, Passegué E. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell. 2009 Apr 07; 15(4):341-52. PMID: 19345332; PMCID: PMC2669108.
    17. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol. 2009 Mar 17; 7(3):e59. PMID: 19296721; PMCID: PMC2656550.
    18. Braun BS, Lessnick SL. Pediatric malignancies: update on sarcomas and leukemia development in children. Curr Opin Genet Dev. 2009 Feb; 19(1):92-6. PMID: 19186049.
      View in: PubMed
    19. Braun BS, Shannon K. Targeting Ras in myeloid leukemias. Clin Cancer Res. 2008 Apr 15; 14(8):2249-52. PMID: 18413813.
      View in: PubMed
    20. Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood. 2007 May 01; 109(9):3945-52. PMID: 17192389; PMCID: PMC1874575.
    21. Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood. 2006 Sep 15; 108(6):2041-4. PMID: 16720837; PMCID: PMC1895533.
    22. Lauchle JO, Braun BS, Loh ML, Shannon K. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr Blood Cancer. 2006 May 01; 46(5):579-85. PMID: 16261595.
      View in: PubMed
    23. Zhang IH, Zane LT, Braun BS, Maize J, Zoger S, Loh ML. Congenital leukemia cutis with subsequent development of leukemia. J Am Acad Dermatol. 2006 Feb; 54(2 Suppl):S22-7. PMID: 16427986.
      View in: PubMed
    24. Braun BS, Shannon K. The sum is greater than the FGFR1 partner. Cancer Cell. 2004 Mar; 5(3):203-4. PMID: 15050910.
      View in: PubMed
    25. Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004 Jun 01; 103(11):4243-50. PMID: 14982883.
      View in: PubMed
    26. Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):597-602. PMID: 14699048; PMCID: PMC327193.
    27. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet. 1997 Dec; 17(4):495-7. PMID: 9398859.
      View in: PubMed
    28. Thompson AD, Braun BS, Arvand A, Stewart SD, May WA, Chen E, Korenberg J, Denny C. EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene. Oncogene. 1996 Dec 19; 13(12):2649-58. PMID: 9000139.
      View in: PubMed
    29. Braun BS, Frieden R, Lessnick SL, May WA, Denny CT. Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis. Mol Cell Biol. 1995 Aug; 15(8):4623-30. PMID: 7623854; PMCID: PMC230703.
    30. Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, Shapiro DN. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 1995 Mar 16; 10(6):1229-34. PMID: 7700648.
      View in: PubMed
    31. Lessnick SL, Braun BS, Denny CT, May WA. Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene. 1995 Feb 02; 10(3):423-31. PMID: 7845667.
      View in: PubMed
    32. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, Hromas R, Denny CT. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol. 1993 Dec; 13(12):7393-8. PMID: 8246959; PMCID: PMC364810.
    33. Ku G, Kronenberg M, Peacock DJ, Tempst P, Banquerigo ML, Braun BS, Reeve JR, Brahn E. Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen. Eur J Immunol. 1993 Mar; 23(3):591-9. PMID: 7680609.
      View in: PubMed
    34. Lewis BC, Shah NP, Braun BS, Denny CT. Creation of a yeast artificial chromosome fragmentation vector based on lysine-2. Genet Anal Tech Appl. 1992 Jun; 9(3):86-90. PMID: 1476795.
      View in: PubMed
    Back to TOP